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The natural history of coronavirus disease 2019 (COVID-19) has yet to be fully described.
Here, we use patient-level data from the Information System for Research in Primary
Care (SIDIAP) to summarise COVID-19 outcomes in Catalonia, Spain. We included 5,586,521
individuals from the general population. Of these, 102,002 had an outpatient diagnosis
of COVID-19, 16,901 were hospitalised with COVID-19, and 5273 died after either being
diagnosed or hospitalised with COVID-19 between 1st March and 6th May 2020. Older age,
being male, and having comorbidities were all generally associated with worse outcomes.
These findings demonstrate the continued need to protect those at high risk of poor
outcomes, particularly older people, from COVID-19 and provide appropriate care for those
who develop symptomatic disease. While risks of hospitalisation and death were lower for
younger populations, there is a need to limit their role in community transmission.
https://doi.org/10.1038/s41467-021-21100-y OPEN
1 Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. 2 Centre for Statistics in Medicine
(CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK. 3 Biostatistics Unit
at Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet, Barcelona, Spain. 4 Universitat de Barcelona, Barcelona, Spain. 5 Universitat Autònoma de
Barcelona, Bellaterra, Spain. ✉email: daniel.prietoalhambra@ndorms.ox.ac.uk









The natural history of coronavirus disease 2019 (COVID-19) has yet to be well-established. While a wide range ofstudies have described outcomes among patients hospita-
lised with COVID-191,2, these individuals represent only a frac-
tion of those who develop symptomatic disease. Similarly, while
outcomes for tested populations have also revealed important
insights3,4, COVID-19 testing has often been prioritised on the
basis of individuals’ symptoms or perceived risk of outcomes,
making inferences about specific risk factors for progression
among these populations difficult5.
A full description of the natural history of COVID-19 from
symptomatic to severe disease is needed. Such a description
requires comprehensive patient-level data that captures incident,
symptomatic cases from a representative population, with sub-
sequent longitudinal follow-up, and where outcomes such as
hospitalisations and mortality, both inside and outside of the
hospital setting, can be identified. Moreover, assessing the impact
of chronic health conditions on the course of the disease requires
comprehensive data on patients’ medical histories. Linked real
world data from countries with universal taxpayer-funded pri-
mary care-based health systems where general practitioners are
the first point of contact for care, and where this role has been
maintained in the response to COVID-19, provide a unique
opportunity for this purpose.
In Spain, one of the European countries worst hit by the
COVID-19 pandemic, primary care has continued to play an
important role in the response to the disease. In Catalonia, an
autonomous region of Spain with a devolved health system, more
than 120,000 outpatient cases of COVID-19 were diagnosed
between 15th March and 24th April 20206. Meanwhile, a
nationwide seroprevalence study conducted between 27th April
to 11th May, 2020 found the prevalence of IgG antibodies to be
around 5% in Spain, and 7% in Catalonia7. Consequently, despite
the burden of disease already experienced, there is a need to
better understand the features of COVID-19 so as to inform the
continued regional, national, and global responses to it.
In this study, our first aim was to summarise COVID-19
related outcomes in Catalonia as experienced during the first
wave of the pandemic. Subsequently, we aimed to describe the
associations between age, sex, and comorbidities and risks of
COVID-19 diagnosis, hospitalisation with COVID-19, and a
COVID-19-related death during the first wave of COVID-19 in
Catalonia. It should be stressed that these latter research ques-
tions are inferential, assessing the existence of relationships but
not the underlying mechanisms or reasons for them8.
Results
Study participants and observed outcomes. A total of 5,586,521
participants were included in the study (Fig. 1). Based on the
study eligibility criteria described above, 169,575 individuals were
excluded due to a lack of a year of prior history, one for having a
COVID-19 positive test prior, 307 for having a prior COVID-19
diagnosis, and three for having a COVID-19 hospitalisation prior
to the 1st March 2020. A further 1207 individuals who were
hospitalised on the 1st March 2020 and 40,999 who were care
home residents were also excluded (a flow chart is provided in
Supplementary Fig. 1). The characteristics of the final study
population are summarised in Table 1. A histogram of the age
distribution of the study population can be seen in Fig. 2, with a
summary of comorbidities shown in Fig. 3.
Out of the included study population, 102,002 went on to
have an outpatient diagnosis of COVID-19 (67-day cumulative
incidence: 1.83%). Of those diagnosed in outpatient settings,
2581 died with COVID-19 without being hospitalised (45-day
cumulative incidence: 3.01%). In total, 16,901 individuals had a
hospitalisation with COVID-19, with 8860 of them having
previously had an outpatient diagnosis (45-day cumulative
incidence: 9.06%). Of those hospitalised, 2692 had died with
COVID-19 by the end of follow-up (45-day cumulative
incidence: 19.16%), see Fig. 1 and Table 2. An extensive
summary of the observed data can be seen alongside the study
code at https://github.com/SIDIAP/MultiStateCovid-19.
The association between age and risk of COVID-19 diagnosis,
hospitalisation, and death. Age profiles varied by transition, see
Table 1. While the median age of the study population as a
whole was 43 (interquartile range: 25–60), those diagnosed with
Fig. 1 Multi-state model of COVID-19. The entire study population began in the general population state as of the 1st March 2020, with progression
through the model possible up to 6th May 2020.
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COVID-19 were 46 (35–58), and those hospitalised without an
outpatient diagnosis were 71 (58–80). Individuals hospitalised
after a diagnosis of COVID-19 were on average 60 (49–73) years
old, and those who died after being diagnosed with COVID-19
(but who were not admitted to hospital beforehand) had an
median age of 85 (76–90). Individuals who died after being
hospitalised had a median age of 80 (73–86).
Estimated hazard ratios for age are shown in Fig. 4 and
summarised in full detail in Supplementary Tables 1 to 19. A
non-linear relationship can be seen for outpatient diagnosis with
COVID-19, with a peak in risks among those aged around 45.
Relative to a reference age of 65, estimated hazard ratios were 0.70
(95% confidence interval: 0.69–0.72) for a 20-year-old, 1.57
(1.55–1.60) for a 45-year-old in the overall model, with age as the
sole explanatory factor. For those at oldest ages, relative hazard
ratios differed in March as compared to April (ie there was non-
proportionality in hazards, which can also be seen in the log-log
plot shown in Supplementary Fig. 2). In March, oldest age was
associated with a lower risk of diagnosis relative to a 65-year-old
(with a hazard ratio of 0.65 [0.62–0.68] for a 90-year-old relative
to a 65-year-old), but in April risks were highest for oldest ages
(with a hazard ratio of 1.68 [1.61–1.76] for a 90-year-old relative
to a 65-year-old).
Risk of hospitalisation with COVID-19 after an outpatient
diagnosis of COVID-19 peaked from around age 75, with
estimated hazard ratios of 0.24 (0.23–0.26) for a 45-year-old,
1.20 (1.17–1.23) for a 70-year-old, and 1.22 (1.14–1.31) for a 90-
year-old, all relative to a reference age of 65 years old.
Older age was associated with an increased risk of hospitalisa-
tion with COVID-19 without a prior diagnosis, death after being
hospitalised with COVID-19, and, in particular, death after being
diagnosed but without being hospitalised. An age of 90 years old
was associated with hazard ratios, relative to 65 years old, of 2.91
(2.75–3.08), 8.28 (7.34–9.34), and 26.00 (23.62–28.62) for each of
these, respectively. For an age of 20, these relative hazard ratios
were all estimated to be less than 0.1. Models estimated separately
by region gave broadly comparable results, see Fig. 4. Associations
between age and diagnosis with COVID-19 varied by sex, with
the peak in risk at middle age more pronounced among women,
while increased risks at oldest ages were seemingly driven by
Table 1 Patient characteristics of the study population and by multistate transition.








To death To hospitalised
with COVID-19
To death To death
N 5,586,521 102,002 8041 11,327 8860 2581 2692
Days since index
date (median [IQR])
24 [19.0, 32.0] 33
[27.0, 40.0]
26 [21.0, 35.0]
Age (median [IQR]) 43 [25.0, 60.0] 46 [35.0, 58.0] 71 [58.0, 80.0] 85
[76.0, 90.0]




Under 18 966,680 (17.3) 4536 (4.4) 34 (0.4) 9 (0.1) 40 (0.5) <5 <5
18–39 1,437,297 (25.7) 30,530 (29.9) 426 (5.3) 80 (0.7) 850 (9.6) 5 (0.2) 11 (0.4)
40–59 1,785,852 (32.0) 44,493 (43.6) 1776 (22.1) 657 (5.8) 3441 (38.8) 63 (2.4) 142 (5.3)
60–69 615,538 (11.0) 10,305 (10.1) 1558 (19.4) 1026 (9.1) 1673 (18.9) 131 (5.1) 292 (10.8)
70–79 468,662 (8.4) 6120 (6.0) 2162 (26.9) 1967 (17.4) 1602 (18.1) 406 (15.7) 822 (30.5)
80 or older 312,492 (5.6) 6018 (5.9) 2085 (25.9) 7588 (67.0) 1254 (14.2) 1976 (76.6) 1424 (52.9)
Sex = female (%) 2,831,062 (50.7) 59,006 (57.8) 3439 (42.8) 5672 (50.1) 3989 (45.0) 1467 (56.8) 1075 (39.9)
Region (%)
Barcelona 4,169,520 (74.6) 82,702 (81.1) 7201 (89.6) 8694 (76.8) 7604 (85.8) 2164 (83.8) 2393 (88.9)
Girona 557,006 (10.0) 9929 (9.7) 432 (5.4) 942 (8.3) 657 (7.4) 217 (8.4) 158 (5.9)
Lleida 370,570 (6.6) 5621 (5.5) 211 (2.6) 728 (6.4) 391 (4.4) 108 (4.2) 94 (3.5)
Tarragona 489,378 (8.8) 3748 (3.7) 196 (2.4) 958 (8.5) 207 (2.3) 92 (3.6) 45 (1.7)
Missing 47 (0.0) <5 <5 5 (0.0) <5 <5 <5
Charlson comorbidity index (%)
0 4,558,137 (81.6) 80,214 (78.6) 3627 (45.1) 1613 (14.2) 5385 (60.8) 365 (14.1) 583 (21.7)
1 400,005 (7.2) 8996 (8.8) 1036 (12.9) 1607 (14.2) 1031 (11.6) 519 (20.1) 427 (15.9)
2 357,892 (6.4) 6846 (6.7) 1409 (17.5) 2304 (20.3) 1164 (13.1) 460 (17.8) 559 (20.8)
3+ 270,487 (4.8) 5946 (5.8) 1969 (24.5) 5803 (51.2) 1280 (14.4) 1237 (47.9) 1123 (41.7)
Autoimmune
condition (%)
273,496 (4.9) 6251 (6.1) 806 (10.0) 1285 (11.3) 727 (8.2) 275 (10.7) 326 (12.1)
Chronic kidney
disease (%)
202,102 (3.6) 3934 (3.9) 1408 (17.5) 3710 (32.8) 892 (10.1) 887 (34.4) 819 (30.4)
COPD (%) 119,950 (2.1) 2359 (2.3) 740 (9.2) 1457 (12.9) 463 (5.2) 261 (10.1) 363 (13.5)
Dementia (%) 42,579 (0.8) 1933 (1.9) 429 (5.3) 2701 (23.8) 294 (3.3) 990 (38.4) 376 (14.0)
Heart disease (%) 533,261 (9.5) 10,732 (10.5) 2611 (32.5) 5686 (50.2) 1903 (21.5) 1175 (45.5) 1324 (49.2)
Hyperlipidemia (%) 515,045 (9.2) 10,820 (10.6) 1498 (18.6) 1580 (13.9) 1507 (17.0) 381 (14.8) 508 (18.9)
Hypertension (%) 689,436 (12.3) 13,747 (13.5) 2405 (29.9) 3834 (33.8) 2206 (24.9) 896 (34.7) 932 (34.6)
Malignant
neoplasm (%)
291,535 (5.2) 5595 (5.5) 1327 (16.5) 3751 (33.1) 991 (11.2) 588 (22.8) 670 (24.9)
Obesity (%) 928,163 (16.6) 20,761 (20.4) 3216 (40.0) 3184 (28.1) 3103 (35.0) 695 (26.9) 1088 (40.4)
Type 2 diabetes (%) 317,505 (5.7) 6000 (5.9) 1644 (20.4) 2612 (23.1) 1284 (14.5) 590 (22.9) 710 (26.4)
Counts of less than 5 have been obscured to protect patient privacy.
COPD chronic obstructive pulmonary disease, IQR interquartile range.
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males. Adjustment for comorbidities generally attenuated the
associations for older ages to some degree, but not in their
entirety (see Supplementary Tables).
The association between sex and risk of COVID-19 diagnosis,
hospitalisation, and death. Compared to the study population as
a whole, which was 51% female, a greater proportion of females
were diagnosed with COVID-19 (58%), but more males (57%)
transitioned directly to being hospitalised with COVID-19 with-
out a previous outpatient diagnosis. Of those diagnosed, more
males (55%) were subsequently hospitalised, but more females
(57%) died without having been hospitalised. Of those hospita-
lised, 60% of those who died were male, see Table 1.
After adjustment for age, male sex was associated with a reduced
risk of outpatient COVID-19 diagnosis (hazard ratio: 0.75 [95% CI:
0.74–0.75]). Conversely, male sex was associated with an increased
risk of all other transitions (Fig. 5). Age-adjusted hazard ratios for
males were 1.64 (1.57–1.72) for hospitalisation with COVID-19
without outpatient diagnosis, 1.77 (1.70–1.85) for hospitalisation
after outpatient diagnosis of COVID-19, 1.33 (1.23–1.44) for death
after outpatient diagnosis of COVID-19, and 1.31 (1.21–1.42) for
death after hospitalisation with COVID-19. The overall increased
risk of diagnosis with COVID-19 for females appeared to be driven
by younger women, with an age-adjusted hazard ratio of 0.72
(0.71–0.73) for males, relative to females, among those 70 years old
or younger, while the hazard ratio for those over 70 years old was
1.11 (1.07–1.15). The increased risk of death following diagnosis
with COVID-19 appeared more pronounced among men younger
than 70, while the increased risk of death following hospitalisation
with COVID-19 for men appeared to be more pronounced in
March (see Fig. 6 and Supplementary Table 17). Estimates were
broadly consistent across by region, and further adjustment for
comorbidities made relatively little difference to these estimates (see
Supplementary Tables 16 to 18).
The association between comorbidities and risk of outpatient
COVID-19 diagnosis, hospitalisation, and death. Comorbidity
profiles varied across different stages of the natural history
of COVID-19, see Table 1 and Fig. 2. The highest proportion
of otherwise healthy participants (Charlson index score of 0)
was seen among those diagnosed with COVID-19 in outpatient
settings (79%), and lowest amongst those who died after an
outpatient diagnosis without hospital admission (14%). While,
for example, the prevalence of chronic kidney disease, COPD,
obesity, and type 2 diabetes were 4%, 2%, 17%, and 6%, respec-
tively, among the study population as a whole, the prevalence of
these conditions was 30, 14, 40, and 26% among those who died
after being hospitalised with COVID-19. Of those individuals that
died after diagnosis of COVID-19 without having being hospi-
talised, 38% had dementia (see Table 2).
After adjustment for age and sex, dementia had the strongest
association with risk of outpatient diagnosis with COVID-19
(hazard ratio: 3.09 [95% CI: 2.94–3.24]), see Fig. 6. Aside from
malignant neoplasm, all other comorbidities were associated with
increased risks of outpatient diagnosis, with estimated hazard
ratios between 1.08 (1.05–1.11) for type 2 diabetes to 1.23
(1.21–1.25) for obesity. Similarly, all conditions were associated
with an increased risk of hospital admission for COVID-19
without a previous outpatient diagnosis, with obesity (hazard
ratio: 1.78 [1.70–1.87]) and dementia (1.86 [1.68–2.06]) asso-
ciated with the greatest excess risks.
Dementia was associated with a reduced risk of hospitalisation
after diagnosis, but an increased risk of death without
hospitalisation, with age and sex adjusted hazard ratios of 0.66
Fig. 2 Histogram of age, by sex, for the study population and by transition in the multistate model. The ages, split by sex, of the study population as a
whole (general population) and of those individuals making transition from general population to diagnosed with COVID-19 and hospitalised with COVID-
19, from diagnosed with COVID-19 to hospitalised with COVID-19 and death, and from hospitalised with COVID-19 to death.
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(0.58–0.75) and 2.84 (2.60–3.09), respectively. Aside from COPD
where no association was seen, all other conditions were
associated with an increased risk of hospitalisation after out-
patient diagnosis, ranging from a hazard ratio of 1.05 (0.98–1.13)
for malignant neoplasm to 1.57 (1.50–1.64) for obesity.
While fewer conditions appeared associated with an increased
risk of death following outpatient diagnosis (without hospitalisa-
tion), malignant neoplasm had a hazard ratio of 1.13 (1.03–1.24),
chronic kidney disease had one of 1.24 (1.14–1.35), and type 2
diabetes one of 1.42 (1.29–1.56). Among those hospitalised, while
little difference in outcomes was seen for those with hyperlipi-
daemia and hypertension after adjusting for age and sex, other
conditions were associated with increased risks with hazard ratios
ranging from 1.09 (1.01–1.18) for obesity to 1.98 (1.77–2.22) for
dementia.
The association between the Charlson comorbidity index and
transitions was most clearly seen for the risks of hospitalisation
without a previous diagnosis and of death following an outpatient
diagnosis with COVID-19 without hospitalisation. A score of
three or more was, relative to a score of zero, associated with age
and sex adjusted hazard ratios of 2.33 (2.18–2.48) and 2.59
(2.28–2.94), respectively.
Results for analyses stratified by age and sex are also shown in
Fig. 6. It can be seen that various comorbidities were associated
with an even greater increase in risk for younger, and particularly
female, study participants for a number of transitions. Obesity,
for example, was associated with hazard ratios of 2.69 (2.43–2.97)
and 2.11 (1.95–2.28) for hospitalisation from general population
and hospitalisation after a diagnosis with COVID-19 among
females, 70 years old or younger. While most associations
between comorbidities and transitions were consistent across
calendar time, dementia was associated with a greater increase in
risk during April than in March. Dementia was associated with
age and sex adjusted hazard ratios of 2.07 (1.91–2.25) and 1.33
(1.15–1.54) for transitions from general population to diagnosis
with COVID-19 and hospitalisation with COVID-19 in March.
These increased to 4.26 (4.00–4.54) and 2.93 (2.52–3.40) in April,
respectively (see Supplementary Table 20 and Supplementary
Fig. 3). Associations between comorbidities and transitions were
seen to be broadly consistent across regions (see Supplementary
Table 21 and Supplementary Fig. 4).
Discussion
In this large cohort study, primary care data from 5,586,521
individuals with linked COVID-19 testing, hospitalisation, and
mortality data has allowed for a detailed characterisation of the
natural history of symptomatic COVID-19 as seen during the
Fig. 3 Prevalence of comorbidities among the general population and by transition in the multistate model. The proportion of the study population as a
whole (general population) with a comorbidity of interest, and of those individuals making transition from general population to diagnosed with COVID-19
and hospitalised with COVID-19, from diagnosed with COVID-19 to hospitalised with COVID-19 and death, and from hospitalised with COVID-19 to death.
COPD chronic obstructive pulmonary disease.
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Fig. 4 Age and COVID-19 transitions. Estimated hazard ratios for age (relative to a reference age of 65) from cause-specific Cox models for each
transition. Dotted lines represent 95% confidence intervals. The models shown included age as the only explanatory variable, with the overall models and
models stratified by calendar month, sex, and region presented.
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Fig. 5 Sex and COVID-19 transitions. Estimated hazard ratios for male sex (relative to female) from cause-specific Cox models for each transition. Points
give estimated hazard ratios, with lines representing 95% confidence intervals. The models shown included sex and age as explanatory variables, with the
overall models and models stratified by calendar month, sex, and region presented.
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first-wave of the epidemic in Spain. Over 100,000 outpatient
COVID-19 diagnoses, close to 17,000 hospitalisations with
COVID-19, and almost 5300 COVID-19 related deaths were
observed between 1st March and 6th May. Of these deaths, half
were among individuals who were diagnosed with COVID-19 in
outpatient settings but were not seen to have been admitted to
hospital.
Older age was consistently associated with increased risks of
hospitalisation and mortality, most dramatically for risk of death
following an outpatient diagnosis of COVID-19 without a sub-
sequent hospital admission. There was though a notable peak in
risk of outpatient diagnosis for people in middle-age during
March, whereas in April risks were highest for oldest ages. A
differential association was seen with sex; while women were at
increased risk of outpatient diagnosis, men were consistently at
higher risk of hospitalisation and death. Finally, the specific
comorbidities studied (autoimmune condition, chronic kidney
disease, chronic obstructive pulmonary disease, dementia, heart
disease, hyperlipidemia, hypertension, malignant neoplasm,
obesity, and type 2 diabetes), and a composite comorbidity index
(Charlson Comorbidity Index) were associated with worse out-
comes. In a number of cases the increase in risk associated with
comorbidities appeared to be particularly pronounced for women
aged under 70.
Older age has consistently been found to be a risk factor for
worse outcomes in COVID-19. It has been associated with an
increased risk of hospitalisation after testing positive for
COVID-193,4, worse outcomes among those hospitalised1,2,9,
and an increased risk of COVID-19-related mortality among
the general population10. Similarly, in our study we find older
age to be associated with poorer outcomes. Our findings suggest
that not only is older age associated with increased disease
severity, but that there was also likely inequitable access to care
during the height of the pandemic in Spain. The increase in risk
for age was most strongly seen for the transition from diagnosis
to death with no admission to hospital seen between the two,
while the risk of hospitalisation itself was also seen to fall at
oldest ages. This may reflect, in part, rationing of health care
resources, with younger patients likely prioritised for the
receipt of hospital care, and intensive services if admitted. With
half of the deaths in this study observed among those not
hospitalised after diagnosis, who had an median age of 86, it is
of utmost importance that similar individuals should be given
appropriate access to care in the future.
Our findings on outpatient diagnoses of COVID-19 may
provide further insights on community transmission of
COVID-19. A peak in diagnosis of COVID-19 was seen among
individuals around the age of 45 years old during March, but by
April the risks of diagnosis were highest for those at oldest ages.
While this could to some degree reflect differences in health
seeking behaviour across age groups and changes in the way in
which diagnoses were made and recorded, it likely also reflects
differences in infection rates across age groups and transmis-
sion dynamics. A large study in Spain found that ser-
oprevalence rose until plateauing at around age of 45 based on
point-care-tests, but that seroprevalence was lower for those
older than 85 compared to younger adults given immunoassay
results7. Meanwhile, a seroprevalence study in Geneva found
that those aged between 20 and 49 had the highest likelihood of
being seropositive11. Consequently, while they face lower risks
of poor outcomes if infected, younger age groups were infected
and appear to have contributed to the spread of the virus in the
community.
Being male has also been associated with worse prognosis in
COVID-19, with increased risks for both hospitalisation among
those tested3, and worse outcomes among those hospitalised2,3,9.
Fig. 6 Comorbidities and COVID-19 transitions. Estimated hazard ratios for comorbidities of interest from cause-specific Cox models for each transition.
Points give estimated hazard ratios, with lines representing 95% confidence intervals. Models were estimated separately for each comorbidity of interest,
with adjustment for age and sex. COPD chronic obstructive pulmonary disease.
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Our data are compatible with previous literature, with risks of
hospital admission and mortality all increased for males. How-
ever, we found the opposite effect for outpatient diagnosis, with
women being at increased risk of diagnosis with COVID-19 in the
community. While this finding contrasts with two UK studies,
which reported a higher risk of testing positive for SARS-CoV-2
among men12,13, it is congruent with the findings from a study
from China that reported a higher attack rate among women14. In
Spain, seroprevalence was seen to be similar for males and
females7. Further research is therefore needed to understand this
finding, which could be explained by differences in exposure and/
or vulnerability to severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2), and differences in health seeking behaviour
between men and women.
Comorbidities have been associated with worse outcomes in
COVID-19 in this study. In line with our findings, those with a
higher Charlson score testing positive for COVID-19 have pre-
viously been seen to have an increased risk of hospitalisation and
death4. Dementia was seen in our study to be associated with a
much-increased risk of diagnosis with COVID-19. For those
diagnosed, dementia was associated with a reduced risk of hos-
pitalisation, but an increased risk of death without hospitalisation.
As with age, the association between dementia and risk of
diagnosis and hospitalisation with COVID-19 in the general
population were seen to change over calendar time, with
increased risks particularly pronounced in April. Other comor-
bidities were seen to be associated with worse outcomes, which
is in accordance with previous findings on outcomes for indivi-
duals with chronic kidney disease, COPD, heart disease, hyper-
lipidemia, hypertension, cancer, obesity, and type 2 diabetes
mellitus2–4,12,13,15. Our findings have also generally shown the
associations between type 2 diabetes, obesity, and chronic kidney
disease and COVID-19 outcomes to be most pronounced among
women under 70. Fewer studies have assessed the relationship
between autoimmune conditions and COVID-19 outcomes. As
with other comorbidities, we found autoimmune conditions to be
associated with an increased risk of poorer outcomes in COVID-
19. Further research is though certainly merited to consider each
of these conditions in turn and consider the impact of other
factors such as these individuals’ medication use.
Our study was informed by routinely-collected health care data
with various interactions between individuals and the health
system identified, covering outpatient diagnoses, COVID-19
testing, and hospitalisations, and with linked mortality data.
This though unavoidably misses health outcomes experienced by
individuals that do not lead to any interaction with the health
care system, with both asymptomatic individuals and a sizeable
proportion of mild symptomatic cases unlikely to be seen. Some
of the clinical diagnoses observed in the study may also represent
false positives, given the uncertainty surrounding the presentation
of the disease during the study period. We did not require clinical
diagnoses to be confirmed by the presence of a positive RT-PCR
test, as such tests were not being routinely performed in out-
patient settings in Spain during the study period. Deaths from
COVID-19 where individuals were not tested or diagnosed
beforehand will also not have been identified.
While providing a broad picture of clinical trajectories, each of
the studied states and transitions can, and should, be considered
in further detail. Analyses of the provision of intensive care
admissions during hospitalisation is one such example, but would
require further data with sufficient granularity on inpatient
treatment. In addition, emergency room presentations that did
not lead to a hospital admission were also not assessed in this
study. Similarly, the set of comorbidities considered here are only
a subset of the myriad set of conditions that are of interest
when considering potential risk factors for COVID-19. Our
classifications are broad, and we have not attempted to split
conditions by severity or concurrent medication use.
The purpose of this study was descriptive in nature. The aim
was not prediction, nor was it causal inference. In particular, it
should be noted that associations between specific comorbidities
and outcomes do not necessarily reflect a causal relationship.
Assessing whether a particular chronic condition is the cause
worse outcomes in COVID-19 will require further consideration
of, and accounting for, relevant confounding factors. The
associations which have been described here are also not
immutable, but rather sit in the context of the first wave of
COVID-19 in Spain. While there is substantial evidence that
individuals at older age are at highest risk of severe disease if
infected, effective shielding strategies would affect the risks of
COVID-19 diagnoses and hospitalisations among this group.
Similarly, ensuring that there is sufficient capacity to provide
appropriate care would likely have a particular impact on the
proportion of patients that die after a diagnosis with COVID-19
without a hospital admission.
In conclusion, in this descriptive study we provide a compre-
hensive overview of the natural history of symptomatic COVID-
19 in Catalonia, Spain, during the first wave of the pandemic. The
findings from this study can help inform the continued response
to COVID-19 both in Spain and elsewhere. Our research has
helped to reveal a clear need to protect at risk populations, par-
ticularly older people, whilst also considering middle-age popu-
lations at a particularly high risk of milder infections and
therefore likely key in the community transmission of the disease.
Methods
Study design. This study was informed by primary care records from Catalonia,
Spain, which were linked to COVID-19 test results, hospital records, and mortality
data. The resulting database was comprehensive, allowing for the identification of
various key events in the progression of COVID-19 over the study period, which
began on the 1st March 2020 and ended on the 6th May 2020. A multistate cohort
model provided the framework for analysis, allowing for a systematic consideration
of transitions for the general population to diagnosis of COVID-19, hospitalisation
with COVID-19, and COVID-19 mortality.
Study participants, setting, and data source. Individual-level routinely-collected
primary care data were extracted from the Information System for Research in
Primary Care (SIDIAP; www.sidiap.org) database, which captures patient records
from approximately 80% of the Catalan population and is representative in geo-
graphy, age, and sex16. Linkage was made at an individual-level to COVID-19 RT-
PCR testing data, hospital data, and regional mortality data.
The entire database has been mapped to the Observational Medical Outcomes
Partnership (OMOP) Common Data Model (CDM). This provided a means of
structuring the data to a standardised format, and allowed for the application of
analytical tools developed by the open-science Observational Health Data Sciences
and Informatics (OHDSI) network17.
All individuals in SIDIAP as of the 1st March 2020 were identified. So that
study participants had sufficient prior observation time for comorbidities to be
identified, any individuals with less than one year of prior history available were
excluded. As the index date for all individuals in the multistate model, described
below, began on the 1st March, any individual who had a clinical diagnosis or
positive test result for COVID-19 between the 1st January and 29th February 2020
was excluded. In addition, because the starting state in the model was
representative of individuals living in the community in Catalonia, individuals who
were hospitalised or a care home resident as of the 1st March 2020 were also
excluded. Study follow-up began on the 1st March 2020 and ended on the 6th May
2020 (the last date of available data).
Variables. Individuals’ age and sex were extracted. Health conditions, using
individual’s observed medical history were identified. The Charlson comorbidity
index was calculated and scores were categorised as 0, 1, 2, or 3+. Ten specific
health conditions were also extracted, all of interest as potential risk factors for the
progression of COVID-19. Autoimmune condition (which included type 1 dia-
betes, rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, systemic
lupus erythematosus, Addison’s disease, Grave’s disease, Sjorgen’s syndrome,
Hashimoto thyroiditis, Myasthenia gravis, vasculitis, pernicious anaemia, celiac
disease, scleroderma, sarcoidosis, ulcerative colitis, and Crohn’s disease), chronic
kidney disease, chronic obstructive pulmonary disease (COPD), dementia, heart
disease, hyperlipidemia, hypertension, malignant neoplasm excluding non-
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melanoma skin cancer, type 2 diabetes mellitus were each identified on the basis of
diagnosis codes. Obesity was identified either by a diagnosis code, a record of a
body mass index measurement between 30 and 60 kg/m2, or a recorded weight
between 120 and 200 kg within 5 years of the index date. The region in which an
individual lived; Barcelona (inclusive of the Barcelona, Metro area north, Metro
area south, and Catalunya Central health regions), Girona, Lleida (inclusive of both
Lleida and Alt Pirineu i Aran health regions), or Tarragona (inclusive of the
Tarragona and Terres de l’Ebre health regions) as of their index date was identified,
as was whether they were a care home resident.
Study outcomes included an outpatient clinical diagnosis of COVID-19, a
hospitalisation with COVID-19, and death. Outpatient COVID-19 diagnoses were
identified on the basis of the first observation of a compatible clinical code being
recorded for COVID-19 disease (such as ICD-10-CM codes B34.2 “Coronavirus
infection, unspecified” and B97.29 “Other coronavirus as the cause of diseases
classified elsewhere”). Hospitalisation with COVID-19 was identified as a hospital
admission, a hospital stay of at least one night, where the individual had a positive
RT-PCR test result or a clinical diagnosis of COVID-19 over the 21 days prior to
their admission up to the end of their hospital stay18. Mortality was identified using
region-wide mortality data, and so included both deaths during hospitalisations
and in the community.
Statistical methods
Multistate model. A multistate model provided the framework for the analysis.
Multistate models allow for a consideration of individuals progression to multiple
events of interest, extending on competing risk models by also describing transi-
tions to intermediate events19. In the context of COVID-19, clinical diagnoses of
the disease and hospitalisations with the disease can be considered as key inter-
mediate events between not being infected (or at least, not having been identified as
being so) on one end to death on the other.
The structure of the multi-state model used in this study is shown in Fig. 1.
There were four states: general population, outpatient diagnosis with COVID-19,
hospitalised with COVID-19, and death. The model is progressive with all
individuals beginning in the general population state (as described above,
individuals included in the study had no prior history of COVID-19 and were not
hospitalised on their index date). Six transitions were possible: from general
population to outpatient diagnosis with COVID-19, from general population to
hospitalised with COVID-19 (i.e., individuals who did not get a clinical diagnosis
prior to hospital admission), from general population to death, from outpatient
diagnosis with COVID-19 to hospitalised with COVID-19, from outpatient
diagnosis with COVID-19 to death, and from hospitalised with COVID-19 to
death. Given the research objectives, the analyses focused on the five transitions
directly related to COVID-19, with the general population to death used primarily
as a means of accounting for the competing risk of death for the study population
(although it should be noted that individuals who died with COVID-19, but had
not been diagnosed or received a positive test will also be included in this
transition).
The index date for all individuals, from which follow-up began, was 1st March
2020. For any given transition in the model, an individual´s end of follow-up was
whichever came first: their exit from the database (administrative censoring), the
occurrence of the event of interest, the occurrence of a competing event, or the end
of the study period (6th May 2020).
Describing the association between age and risk of COVID-19 diagnosis, hospitali-
sation, and death. Our objective here was to describe the overall association
between age and outcomes seen during the first wave of COVID-19 in Catalonia.
Consequently, the primary models of interest included age as the sole explanatory
factor.
The relationship between age and the risk of each transition in the multistate
model was assessed by estimating cause-specific Cox models, with hazard ratios
and 95% confidence intervals (95% CIs) calculated. A non-linear relationship
between age and the risk of transitions was considered by fitting age with a
polynomial of degree 2 (i.e., quadratic) and with restricted cubic splines (with 3, 4,
or 5 knots)20. Comparisons between these, and a model where age was assumed to
have a linear relationship, were made using Akaike information criterion (AIC)
and Bayesian Information Criterion (BIC). Where a more parsimonious model was
seen to well-approximate a more complex one, the simpler model was favoured.
Non-proportionality in hazards was considered through visual inspection of
log–log plots.
To consider whether associations between age and outcomes varied by sex,
models were also estimated separately for males and females. Similarly, models
were also estimated separately for each region. To consider the impact of calendar
time on the association between age and the risk of transitions from general
population to outpatient diagnosis with COVID-19 and hospitalised with COVID-
19, models were estimated separately for March and April (i.e., with follow-up split
into these distinct periods). To consider the impact of calendar time on the
association between age and subsequent transitions (i.e., from outpatient diagnosis
with COVID-19 to hospitalised with COVID-19, outpatient diagnosis with
COVID-19 to death, and from hospitalised with COVID-19 to death), models were
estimated separately for those who arrived into these starting states in March and
those who transitioned into them in April. Additionally, to consider the degree to
which observed associations could be explained by differences in comorbidity
profiles across age groups, models were also estimated with additional adjustment
subsequently made for comorbidities, with the Charlson score and the ten specific
conditions of interest described above also included as explanatory factors in
the model.
Describing the association between sex and risk of COVID-19 diagnosis, hospitali-
sation, and death. Our objective here was to describe the overall association
between sex and outcomes, accounting for differences in age, during the first wave
of COVID-19 in Catalonia. Therefore, the primary models included sex and age,
with the sex the explanatory factor of interest.
As above, the relationship between sex and the risk of each transition in the
multistate model was assessed by estimating cause-specific Cox models. Non-
linearity in age was incorporated in the same way as for the previous research
objective. To consider whether associations between sex and outcomes varied by
age, models were also estimated separately for those aged 70 or younger and those
aged over 70 (with age assumed to have a linear relationship within each of the
strata). Stratified models were also estimated by region and calendar time. An
additional set of models were also estimated with adjustment made for
comorbidities.
Describing the association between comorbidities and risk of transitions. Our
objective here was to describe the overall association between comorbidities and
outcomes, accounting for differences in age and sex, during the first wave of
COVID-19 in Catalonia. The primary models included the specific comorbidity of
interest (the explanatory factor of interest), age, and sex.
The relationship between comorbidities and each transition was assessed by
estimating cause-specific Cox models. Models were estimated for each comorbidity
of interest separately, controlling for age and sex and with non-linearity in age
incorporated in the same way as described above. To consider whether associations
between comorbidities and outcomes varied by age and sex, models were
subsequently estimated stratifying by both age (70 or younger or above 70) and sex,
with age also included as an explanatory factor within each of the strata as a linear
term. For dementia, models were only estimated for the older age strata. Stratified
models were also estimated by region and calendar time.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
In accordance with current European and national law, the data used in this study is only
available for the researchers participating in this study. Thus, we are not allowed to
distribute or make publicly available the data to other parties. However, researchers from
public institutions can request data from SIDIAP if they comply with certain
requirements. Further information is available online (https://www.sidiap.org/index.php/
menu-solicitudes-en/application-proccedure) or by contacting Anna Moleras
(amoleras@idiapjgol.org).
Code availability
The mapping of source SIDIAP data to the OMOP CDM was facilitated by various open-
source OHDSI software, which included usagi (https://github.com/OHDSI/Usagi), to
help define mappings from source codes to the standard concepts used in the CDM, and
Achilles (https://github.com/OHDSI/Achilles), to help assess data quality after mapping.
Data analysis was performed in R version 4.0.0. The R packages used in the analysis
included OHDSI CohortDiagnostics (https://github.com/OHDSI/CohortDiagnostics),
numerous tidyverse packages21, mstate22, and rms23. The analytic code used in this study
is freely available at https://github.com/SIDIAP/MultiStateCovid-19. Cohort definitions
were adapted from those used in the OHDSI Seek COVER study and the OHDSI
CHARYBDIS project24. A web application which summarises the cohort definitions used
is available at https://livedataoxford.shinyapps.io/MultiStateCovidCohorts/.
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